Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcuma wenyujin, a member of the turmeric family, has been used in traditional Chinese medicine, but in recent years, some studies have investigated its potential therapeutic effects on colitis, specifically ulcerative colitis and other forms of inflammatory bowel disease (IBD). The main active components, such as curcuminoids and volatile oils, are believed to possess anti-inflammatory, antioxidant, and immunomodulatory properties.

Preclinical research, primarily in animal models (such as mice with chemically-induced colitis), has shown that extracts or specific compounds isolated from Curcuma wenyujin can reduce colonic inflammation, decrease levels of pro-inflammatory cytokines (like TNF-α and IL-6), and ameliorate histopathological damage. Mechanistic studies suggest that these effects may be due to inhibition of the NF-κB pathway, reduction of oxidative stress, and regulation of immune cell infiltration in the colon.

However, evidence in humans is very limited. No large-scale randomized controlled trials in humans have been published as of mid-2024. Most data come from in vitro studies or animal experiments, and it is not yet clear whether these findings translate to clinical benefit in patients with colitis. As such, while there is emerging scientific interest and some supportive preclinical evidence, the overall strength of evidence is still rated as low (2/5), pending high-quality clinical trials.

More about Curcuma wenyujin
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Curcuma wenyujin

Products containing Curcuma wenyujin